Non-erythroid heme biosynthesis gene, ALAS1, up-regulation after hypomethylating agents predict better outcome in patients with myelodysplastic syndrome

Name: Non-erythroid heme biosynthesis gene, ALAS1, up-regulation after hypomethylating agents predict better outcome in patients with myelodysplastic syndrome
Creator: EDA hospital; I-Shou University; Sheng-Fung Lin; Jung-Sheng Chen; Ching-I Yang; Shih-Cin Lin
Published: 2022-08-28T00:00:00+08:00

Zenodo2022-08-28 更新2026-04-07 收录

骨髓增生异常综合征预后预测

去甲基化治疗反应基因表达

数据链接：

https://zenodo.org/record/7029751 数据链接链接失效反馈

官方服务：

资源简介：

Supplementary Figure: mRNA next generation sequence analysis. (A) mRNA expression of MDS patients treated with AZA. MDS001: MDS with early AZA treatment failure. MDS001_1: before AZA treatment; MDS001_2: under AZA treatment, with response; MDS001_3: AZA treatment failure with leukemia change. MDS002: AZA failure within 2 years. MDS002_1: before treatment; MDS002_2: under AZA treatment, with response. MDS003: long-term AZA treatment response; MDS001: MDS001-1+MDS001-2+MDS001-3. MDS002: MDS002-1 + MDS002-2. MDS003 is MDS003-1

提供机构：

EDA hospital; I-Shou University; Sheng-Fung Lin; Jung-Sheng Chen; Ching-I Yang; Shih-Cin Lin

创建时间：

2022-08-28